Feels nice to have a big winner again; we took for granted how many we used to have. Some analyst reaction today
- Lazard Capital Markets analyst Sean Lavin said SEQureDx will become the standard test for Downs, replacing amniocentesis and hormone screening because of its greater accuracy. He also thinks the test may be more sensitive than the older methods. Lavin raised his price target to $44 per share from $34. "We believe most risk has been removed from the story and that a significant number of risk-averse investors will now look to buy and hold this gamechanging stock," he said.
- Kevin DeGeeter of Oppenheimer and Co. estimated the Downs testing market at $1 billion to $1.5 billion.
6 comments:
Thanks for this one. Must admit I took all my profit today (still nervous).
Maybe I'll get back in again later if it drops or on a overall market move up.
Solar Flyer
I know you don't want to give up your secrets since you're trying to start a fund, but what tools or criteria do you use to find these smaller companies? Do you have a team searching for small caps in certain sectors, etc? Just curious.
I'm a team of 1
I work about 20 hour days, so that's how I find ideas. Hard work.
I do sleep in on Saturdays though ;)
Nice trade, Mark!
OK, when it didn't go down (but up)at the Vix top, I'm back in with half a position - nice one!
"I do sleep in on Saturdays though ;)"
Slacker! ;)
Post a Comment